Turning frustration into innovation
After being diagnosed with follicular lymphoma, AI tech entrepreneur Adam Blum assumed he could easily find the latest treatment options. However, he was met with resistance from doctors and a confusing, fragmented search process. Adam quickly discovered that most existing clinical trial databases weren’t designed for patients—they were built for medical professionals, filled with jargon and requiring detailed knowledge that patients typically don’t have.
This frustrating experience inspired Adam to create a better solution. Drawing on his background in AI, he envisioned a platform that would use technology to bridge the gap between patients and clinical trials. CancerBot was born out of this mission: to make trial matching accessible, personalized, and jargon-free. Today, CancerBot is helping patients like Adam find potential life-saving treatments faster and more easily than ever before.
Our mission and vision
Our mission
To empower cancer patients by making clinical trial access simple, accurate, and patient-focused.
Our vision
A world where every cancer patient has the opportunity to find the best available treatments, regardless of medical expertise or background. We believe that AI can democratize access to potentially life-saving clinical trials, giving patients more choices and more hope.
Meet the People Behind CancerBot
Our team brings decades of experience in AI, medical research, and data science. Together, we’re committed to making clinical trials more accessible and personalized for cancer patients everywhere.
Adam Blum
Founder and CEO
Adam Blum is the founder and technical innovator behind several successful startups including Rhomobile (sold to Motorola in 2011), OpenEd (sold to ACT 2016) and Skillmore (sold to Apollo Education Group 2024). OpenEd and Skillmore were both early pioneers in using AI Large Language Models for until then unsolved problems: inferring skills for educational resources (OpenEd) and inferring skills for corporate employees (Skillmore). Adam wrote what may be the first applied neural networks text (Neural Networks in C++, Wiley, 1992) and has taught courses at both University of California, Berkeley and Carnegie Mellon University. Adam's cancer journey as a follicular lymphoma survivor drove him to the initial development of CancerBot. He is principal inventor on the patent-pending EXACT Clinical Trial Matching system that powers the service.
William Briggs
Director of Biomedical AI
William Briggs began his career in an academic setting, working on a PhD focused on applying NLP to clinical research data and tackling the challenges of medical language. He has since worked as a data scientist across both medical research and patient EMRs, developing NLP tools that extract insights from complex healthcare data. At CancerBot, he bridges the medical annotation and technical teams, helping enhance the platform’s accuracy and performance.
